The estimated Net Worth of Enterprise Associates 12, L... is at least $25.2 Millón dollars as of 30 July 2018. Enterprise L owns over 545,455 units of Liquidia Corp stock worth over $25,221,431 and over the last 9 years Enterprise sold LQDA stock worth over $0.
Enterprise has made over 5 trades of the Liquidia Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently Enterprise bought 545,455 units of LQDA stock worth $6,000,005 on 30 July 2018.
The largest trade Enterprise's ever made was buying 1,869,159 units of Liquidia Corp stock on 5 June 2015 worth over $20,000,001. On average, Enterprise trades about 634,559 units every 164 days since 2015. As of 30 July 2018 Enterprise still owns at least 2,484,870 units of Liquidia Corp stock.
You can see the complete history of Enterprise L stock trades at the bottom of the page.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell y Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: